文献速递膀胱癌与上尿路尿路上皮癌

自动化荧光尿液细胞学用于膀胱癌筛查与监测

Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer.
PubMed 文献 · BJU Int · 2021-04-16

本研究评估了基于新型自动化检测技术的荧光排泄尿液细胞学(FVUC)在原发性膀胱癌筛查和复发肿瘤监测中的诊断性能。结果显示FVUC及联合检测的敏感性显著高于传统VUC,尤其在低级别、Ta期和小肿瘤中优势明显;监测队列中联合检测敏感性82%、阴性预测值98%。

要点

  • FVUC筛查原发性膀胱癌敏感性63%,联合检测72%,均显著高于cVUC的29%。
  • 监测复发肿瘤时联合检测敏感性82%、阴性预测值98%,cVUC分别为39%和96%。
  • FVUC假阴性复发肿瘤多为Ta低级别肿瘤;假阳性风险与尿白细胞高密度和碱性尿相关。

核心结论

  • 基于新型自动化技术的FVUC在原发性膀胱癌筛查和复发肿瘤检测中敏感性均优于传统VUC。
  • 需进一步大规模研究确认临床实用性并确保可负担性和可及性。

研究设计与样本

  • 研究采用两个队列:筛查队列含165例膀胱癌患者和52例对照;监测队列含192例经治疗的非肌层浸润性膀胱癌患者和15例肾输尿管切除术后上尿路癌患者。
  • 共成功收集、处理和分析614份尿液样本,比较cVUC、FVUC及两者联合的诊断性能。

主要发现

  • 筛查队列中FVUC总体敏感性63%(P < 0.001),联合检测72%(P < 0.001),均显著高于cVUC的29%。
  • FVUC在多数亚组中表现更优,尤其在低级别、Ta期和小肿瘤中。
  • 监测队列中联合检测敏感性82%、阴性预测值98%,cVUC分别为39%和96%。
  • FVUC假阴性的复发肿瘤多数为Ta低级别肿瘤。
  • 逻辑回归分析提示假阳性风险与尿白细胞高密度和碱性尿相关。

关键数值与推荐

  • 筛查队列敏感性:FVUC 63%(P < 0.001),联合检测72%(P < 0.001),cVUC 29%。
  • 监测队列:联合检测敏感性82%、阴性预测值98%;cVUC敏感性39%、阴性预测值96%。

临床怎么用

  • 在膀胱癌筛查和复发监测中,可考虑采用FVUC或联合cVUC以提高敏感性。
  • 需注意FVUC对Ta低级别复发肿瘤可能漏诊,假阳性风险与尿白细胞高密度和碱性尿相关。

局限性

  • 需进一步大规模研究确认临床实用性。
  • 需确保方法的可负担性和可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the diagnostic performance of fluorescent voided urine cytology (FVUC) using a novel automated detection technology to screen for primary bladder cancer and for surveillance of recurrent bladder tumour. PATIENTS AND METHODS: We created a rapid, objective, automated, and high-throughput detection device for hexylaminolevulinate-mediated FVUC, named the cellular fluorescence analysis unit-II (CFAU-II). Two different cohorts were used in this study: (i) screening test for primary bladder cancer (165 patients with bladder cancer and 52 controls), and (ii) surveillance test for detecting intravesical recurrent tumour (192 patients with treated non-muscle-invasive bladder cancer and 15 with post-nephroureterectomy upper urinary tract cancer). Voided urine samples were subjected to urine analysis, conventional VUC (cVUC), and FVUC. Diagnostic performance was compared between cVUC, FVUC, and a combination of the two. RESULTS: A total of 614 urine samples were successfully collected, processed, and analysed. Comparative analysis of the screening test cohort demonstrated that the overall sensitivity of FVUC (63%, P < 0.001) and combination testing (72%, P < 0.001) was significantly higher than that of cVUC (29%). FVUC was found to be superior in most of the subgroups, especially in low-grade, Ta, and small tumours. Analysis of the surveillance test cohort showed that combination testing achieved a sensitivity of 82% and a negative predictive value of 98%, whereas those of cVUC were 39% and 96%, respectively. According to the pathological finding of recurrent tumours presenting false-negative result in the FVUC, the majority of the overlooked recurrent diseases were Ta low-grade tumours. Logistic regression analysis suggested an association between the risk of false-positive results and high density of urine white blood cells and alkaluria. CONCLUSION: The present findings clearly demonstrate that FVUC using the newly developed automation technology has superior sensitivity to cVUC for both screening for primary bladder cancer and recurrent tumour detection. It is essential to confirm the clinical usefulness of this method via further large-scale studies, in addition to ensuring its affordability and availability.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Miyake M, Nakai Y, Nishimura N, et al. Hexylaminolevulinate-mediated fluorescent urine cytology with a novel automated detection technology for screening and surveillance of bladder cancer. BJU Int. 2021. PMID: 33580627. doi:10.1111/bju.15368

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。